These data provide a potential explanation for the differences in immune checkpoint inhibitor responses observed in MSI‐H colorectal cancer clinical trials and support the use of MSH6 mutation status for determining the sequence of checkpoint inhibitors and chemotherapy. The gene discussed is MSH6; the disease is colorectal cancer.